Unlearn Health

Unlearn Health is at the forefront of transforming clinical trials with its innovative approach known as TwinRCTs (Twin Randomized Controlled Trials). By leveraging the concept of digital twins, the company creates predictive models for each participant that enable more efficient and accurate assessments of treatment outcomes.

The TwinRCTs methodology allows for a smaller control group and accelerates enrollment times, ultimately leading to quicker decision-making in clinical trials. This is especially beneficial in both early and late-stage research, as it enhances the overall power of the studies without necessitating an increase in participant numbers. Unlearn Health is actively involved in various research domains, including neuroscience and metabolic diseases, and emphasizes increased participant engagement by providing improved probabilities of receiving experimental treatments.

In addition to advancing clinical methodologies, Unlearn Health has successfully navigated the regulatory landscape, obtaining qualifications from the European Medicines Agency (EMA) for its PROCOVA process, which integrates TwinRCTs in phases 2 and 3 of clinical trials. This regulatory success is further supported by the concurrence of the U.S. Food and Drug Administration (FDA) with regards to the efficacy of this methodology.

The company aims to eliminate the traditional trial-and-error approach in medicine by equipping healthcare professionals with AI-driven tools that analyze extensive patient-level data. This strategic use of technology not only accelerates clinical research but also empowers healthcare professionals to make evidence-based decisions, enhancing overall patient care.